MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs

Core Insights - MaxCyte, Inc. has entered into a strategic platform license agreement with TG Therapeutics, allowing TG Therapeutics to utilize MaxCyte's Flow Electroporation® technology and ExPERT™ platform for research, clinical, and commercial purposes [1][2] - In exchange, MaxCyte will receive annual licensing fees and program-related revenue from TG Therapeutics [2] - TG Therapeutics is advancing its investigational allogeneic CD19 CAR T cell therapy, azer-cel, for autoimmune diseases, with plans to commence a Phase 1 trial in 2025 [3][4] Company Overview: MaxCyte - MaxCyte specializes in cell engineering technologies aimed at enhancing the discovery and commercialization of cell-based therapeutics [1] - The ExPERT™ platform is designed to support the growing cell therapy market, providing high transfection efficiency and scalability [4][5] - MaxCyte has over 25 years of experience in developing advanced platforms and technologies for cell therapy applications [5] Company Overview: TG Therapeutics - TG Therapeutics focuses on developing and commercializing novel treatments for B-cell diseases, including a pipeline of investigational medicines [6] - The company has received FDA approval for BRIUMVI® (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis [6]